Get Stock Quote Here AMGen (AMGN) (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, AMGen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
Reported after close today (4/28/16) Earnings: EPS $2.90 Revenue $5.5B Estimates: EPS $2.56 Revenue $5.362B Down 0.03% in after hours so far
Earnings are tomorrow evening. The stock is starting to breakout. Another quality, under owned name that could begin to run if price can remain above $165 - $170. Can earnings tomorrow (7/27/2016) do the trick? A trade above $175 has it trading at $195. Goldman had the stock in its conviction buy list for 2016. Thought it has had its share of ups and downs over the years, Amgen Inc. (NASDAQ: AMGN) is now among the largest biotechs in the world. Some even consider Amgen a Big Pharma in the making. Goldman Sachs has had a Buy rating on Amgen for a while now, but the firm’s recent $213.00 price target would imply over 30% upside in total return (with dividends) from the $164.00 level, if Goldman Sachs is right. Amgen’s Repatha cholesterol drug was one of the strengths cited here, but there is also an abundant return of capital plan from Amgen for its shareholders. Amgen’s all-time high is $181.81, and the consensus price target is almost $189.00. Keep in mind that Goldman Sachs actually has the highest reported price target for Amgen. http://247wallst.com/investing/2015/12/31/5-top-goldman-sachs-stocks-to-buy-for-2016/
That is one ugly chart for anybody that got in last month! Amgen Sinks Despite Beating Street Estimates When Amgen Inc. (AMGN) reported its third-quarter financial results after the markets closed on Thursday, the company said that it had $3.02 in earnings per share (EPS) and $5.81 billion in revenue. Consensus estimates from Thomson Reuters had called for $2.79 in EPS and revenue of $5.74 billion. In the same period of last year, the biotech giant posted EPS of $2.72 and $5.72 billion in revenue. In terms of guidance for the full year, the company expects to have EPS in the range of $11.40 to $11.55 and revenues between $22.6 billion and $22.8 billion. Both forecasts increased from their previous levels. The consensus estimates for the full year are $11.36 in EPS and $22.77 billion in revenue. June support levels in play.
Upcoming dividend information: Ex-Div-Date: 11/14/16 Payment Date: 12/8/16 Dividend: $1.00 Current Price: $135.40 Annual Yield: 2.95%
Up 4.5% pre-market on news that they won the court ruling for a ban of Sanofi's sales of praluent cholesterol drug
thestreet.com Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?
How do they know that you're taking the drug? What if I get the drug and deal (some of) it to another, then get a heart attack? Free money!
Yeah lol. Not sure how long you have to take Repatha, and if the money-back guarantee is for a lifetime. But stay on statins, and get Repatha. Instead of taking the usual dose, maybe half it if you want. Then deal the rest. Hey it's a new sharing economy!
Shares of Amgen ($AMGN) could also move to the downside after Jefferies downgraded its rating on the biotechnology company’s stock to Hold from Buy.
Amgen quarterly profit tops expectations despite sales decline By Bill Berkrot Oct 25 (Reuters) - Amgen Inc reported higher-than-expected third quarter profit on Wednesday as lower costs and improved operating margins helped offset sales declines in some of its most important products. The world's largest biotechnology company also raised its full-year adjusted earnings forecast, but its shares fell in late trading as weaker-than-expected sales of a new drug and declines in sales of key blockbuster products may have spooked investors. Amgen boosted its earnings outlook to $12.50 to $12.70 per share from $12.15 to $12.65 despite taking a financial hit to Puerto Rico operations from Hurricane Maria, which devastated the island last month. Analysts on average were looking for 2017 earnings of $12.58 per share, according to Thomson Reuters data. The low end of Amgen's 2017 revenue forecast range was slightly raised to $22.7 billion with the top end still at $23 billion. Amgen shares, up 21 percent this year, fell 1.5 percent to $174.75 Read More Here: https://finance.yahoo.com/news/amgen-quarterly-profit-tops-expectations-203412295.html
Amgen is working on expanding its presence in international markets, which represent significant commercial potential. Amgen’s acquisition of more than a 99% of shares of a Turkish company, Mustafa Nevzat Pharmaceuticals, has helped expand its presence in Turkey and other rapidly growing important markets. The company expects to generate more than $2 billion in sales from new and emerging markets (Asia, Turkey and the Middle East, Latin America, Russia and Eastern Europe) by 2018.
